Cargando…

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.

Detalles Bibliográficos
Autores principales:	Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Dobbins, Mackenzie, Jain, Nitin, Abbas, Hussein, Kornblau, Steven, Maiti, Abhishek, Veletic, Ivo, Manshouri, Taghi, Bledsoe, Sharon, Ann Richie, Mary, Hall-Moore, Nakiuda, Zhou, Lingsha, Wang, Xuemei, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431428/ http://dx.doi.org/10.1097/01.HS9.0000971000.57384.96

Ejemplares similares

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
por: Veletic, Ivo, et al.
Publicado: (2020)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
por: Manshouri, Taghi, et al.
Publicado: (2022)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER
por: Masarova, L., et al.
Publicado: (2022)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up
por: Masarova, Lucia, et al.
Publicado: (2017)

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2016)

P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS
por: Senapati, J., et al.
Publicado: (2022)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
por: Kvasnicka, Hans Michael, et al.
Publicado: (2018)

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2021)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
por: Verstovsek, Srdan, et al.
Publicado: (2013)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Defining disease modification in myelofibrosis in the era of targeted therapy
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial
por: Jain, Preetesh, et al.
Publicado: (2017)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
por: Masarova, Lucia, et al.
Publicado: (2017)

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
por: Shoukier, Mahran, et al.
Publicado: (2020)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
por: Mughal, Tariq I, et al.
Publicado: (2014)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Targeting cistrome and dysregulated transcriptome of post-MPN sAML
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_97johs3r18ot1tcpg8h1t6oq5n